The pharmacoeconomic efficacy of lurasidone in the treatment of schizophrenia

Dyakov I.N.; Juperin A.A.; Egorova D.A.; Mosolova E.S.

doi:https://doi.org/10.17116/jnevro202012006282

Close metadata

OBJECTIVE

To conduct a comprehensive pharmacoeconomic evaluation of lurasidone for the treatment of patients with schizophrenia under Russian healthcare system conditions and inclusion in EDL (Essential Drugs List) and Medication List for the Certain Categories of Citizens.

MATERIAL AND METHODS

A retrospective study of lurasidone in the treatment of patients with schizophrenia was performed. Methods of pharmacoeconomic analysis were: cost analysis, budget impact analysis and cost-effectiveness analysis.

RESULTS

Use of lurasidone for the treatment of patients with schizophrenia requires 50.04% less costs than the use of paliperidone and 46.69% less costs than the use of sertindole allowing to provide additional therapies to 100.1 and 87.6% of patients, respectively. The cost minimization analysis results are stable when prices fluctuate in the range of ±30%. Considering the current volume of antipsychotic drug supply, replacing 100% of paliperidone with lurasidone from the first year will reduce the cost of antipsychotics for patients who received paliperidone by 39.79 or by 360.81 million rubles over 3 years. Replacing 100% of sertindole with lurasidone from the first year will reduce the cost of antipsychotics for patients who received sertindole by 37.21 or 173.87 million rubles over 3 years. The results of the budget impact analysis are resistant to changes in prices for compared drugs in a wide range.

CONCLUSION

Lurasidone is a more effective drug for treatment of schizophrenia from a pharmacoeconomic point of view in comparison with paliperidone and sertindole. With comparative efficacy with paliperidone and sertindole the use of lurasidone can significantly reduce the burden on budget of state programs of compensation for certain categories of citizens.

Keywords:

schizophrenia

second generation antipsychotics

lurasidone

paliperidone

sertindole

minimization of expenses

analysis of budget impact

clinical and economic analysis

Authors:

I.N. Dyakov

Mechnikov Research Institute of vaccines and serums;
Scientific and Practical Center for Research of Problems of Rational Pharmacotherapy and Pharmacoeconomics

A.A. Juperin

Russian Medical Academy of Continuous Professional Education

D.A. Egorova

Russian Medical Academy of Continuous Professional Education

E.S. Mosolova

Lomonosov Moscow State University

Received:

23.03.2020

Accepted:

13.04.2020

Close metadata

References:

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018;392(10159):1789-1858. https://doi.org/10.1016/S0140-6736(18)32279-7
Mosolov SN. Nekotorye aktualnye teoreticheskie problemy diagnostiki, klassifikatsii, neirobiologii i terapii shizofrenii: sravnenie zarubezhnogo i otechestvennogo podkhodov. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2010;110(6):4-11. (In Russ.).
Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2(5):e141. https://doi.org/10.1371/journal.pmed.0020141
Moreno-Küstner B, Martín C, Pastor L. Prevalence of psychotic disorders and its association with methodological issues. A systematic review and meta-analyses. PLoS One. 2018;13(4):e0195687. https://doi.org/10.1371/journal.pone.0195687
WHO. Mental Health and Development: Targeting People with Mental Health Conditions as a Vulnerable Group. Geneva: World Health Organization Publication; 2010.
Psikhiatricheskaia pomoshch naseleniiu Rossiiskoi federatsii v 2015-2017 gg. Analiticheskii obzor. Pod red. Kekelidze Z.I. M.: FGBU «FMITsPN im. V.P. Serbskogo» Minzdrava Rossii; 2018. (In Russ.).
https://doi.org/10.15690/vramn.v69i7-8.1118 https://doi.org/10.15690/vramn.v69i7-8.1118
Neznanov NG, Martynikhin IA, Mosolov SN. Diagnostika shizofrenii v Rossii: rezultaty onlain-oprosa vrachei-psikhiatrov Chast 1. Ispolzovanie MKB-10. Sovremennaia Terapiia Psikhicheskikh Rasstrojstv. 2019;1:2-13. (In Russ.).
Awad AG, Voruganti LN. The burden of schizophrenia on caregivers: a review. Pharmacoeconomics. 2008;26(2):149-162. https://doi.org/10.2165/00019053-200826020-00005
https://doi.org/10.1093/epirev/mxn011
Gurovich IYa, Shmukler AB, Kostiuk GP, Naryshkin AV. Kontingent bolnykh shizofreniei i rasstroistvami shizofrenicheskogo spektra, poluchaiushchikh lechenie v psikhiatricheskoi bolnitse (po materialam odnodnevnoi perepisi). Sotsialnaia i Klinicheskaia Psikhiatriia. 2013;23(3):48-54. (In Russ.).
Kostiuk GP. Otdalennyi katamnez bolnykh shizofreniei, uvolennykh iz vooruzhennykh sil (s pozitsii mnogoosevoi diagnostiki): Avtoreferat dis ... kand. med. nauk. Saint Petersburg. 1999. (In Russ.).
Goeree R, Farahati F, Burke N, Blackhouse G, O’Reilly D, Pyne J, Tarride JE. The economic burden of schizophrenia in Canada in 2004. Cur Med Res Opin. 2005;21(suppl 12):2017-2028. https://doi.org/10.1185/030079905X75087
Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol. 2005;12(suppl 1):1-27.
Gurovich IIa, Liubov EB. Farmakoepidemiologiia i farmakoekonomika v psikhiatrii. M.: Medpraktika-M; 2003. (In Russ.).
Liubov EB, Iastrebov VS, Shevchenko LS, Chapurin SA, Churilin IuIu, Bylim IA, Gazha AK, Doronin VV, Kosov AM, Petukhov IuL, Fadeev PN. Ekonomicheskoe bremia shizofrenii v Rossii. Sotsialnaia i Klinicheskaia Psikhiatriia. 2012;22(3):36-42. (In Russ.).
Mosolov SN, Potapov AV, Shafarenko AA, Kostiukova AB, Ushakov IuV, Burygina LA, Zabelina IN. Razrabotka i validizatsiia standartizirovannykh kriteriev terapevticheskoi remissii pri shizofrenii. Sovremennaia Terapiia Psikhicheskikh Rasstroistv. 2011;3:2-6. (In Russ.).
Mosolov S, Potapov AV, Ushakov UV, Shafarenko AA, Kostyukova AB. Design and validation of standardized clinical and functional remission criteria in schizophrenia. Neuropsychiatric Disease and Treatment. 2014;10:167-181. https://doi.org/10.2147/NDT.S46799
Mosolov SN, Tsukarzi EE, Alfimov PV. Algoritmy biologicheskoi terapii shizofrenii. Sovremennaia Terapiia Psikhicheskikh Rasstroistv. 2014;1:27-36. (In Russ.).
Mosolov SN, Potapov AV, Ushakov UV. Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an outpatient population. Annals of General Psychiatry. 2012;11:1-12. https://doi.org/10.1186/1744-859X-11-1
Alfimov PV, Ryvkin PV, Ladyzhenskii MYa, Mosolov SN. Metabolicheskii sindrom u bolnykh shizofreniei (obzor literatury). Sovremennaia Terapiia Psikhicheskikh Rasstroistv. 2014;3:8-14.
Mosolov SN, Tsukarzi EE, Kapiletti SG. Antipsikhoticheskaia farmakoterapiia shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiiam. V kn.: Biologicheskie metody terapii psikhicheskikh rasstroistv. Red. Mosolov S.N. Dokazatelnaia meditsina — klinicheskoi praktike. M. 2012.
Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, Samara M, Rabaioli M, Bächer S, Cipriani A, Geddes JR, Salanti G, Davis JM. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. Am J Psychiatry. 2017;174(10):927-942. https://doi.org/10.1176/appi.ajp.2017.16121358
Juckel G, de Bartolomeis A, Gorwood Ph, Mosolov S, Pani L, Rossi A, Sanjuan J. Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatric Disease and Treatment. 2014;10:1867-1878. https://doi.org/10.2147/NDT.S61672
Loebel A, Cucchiaro J, Sarma K, et.al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial. Schizophrenia Research. 2013;145:101-109. https://doi.org/10.1016/j.schres.2013.01.009
Meltzer H, Cucchiaro J, Silva R, et al. Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study. Am J Psychiatry. 2011;168:957-967. https://doi.org/10.1176/appi.ajp.2011.10060907
Rossiiskoe obshchestvo psikhiatrov. Federalnye klinicheskie rekomendatsii po diagnostike i lecheniiu shizofrenii. Pod red. Krasnova V.N. i dr. M. 2013. https://psychiatr.ru/download/1269
Maslenikov NV, Tsukarzi EE, Mosolov SN. Algoritm biologicheskoi terapii depressii pri shizofrenii. Sovremennaia terapiia psikhicheskikh rasstroistv. 2019;2:31-40.
Mosolov SN, Tsukarzi EE. Psikhofarmakoterapiia shizofrenii. V knige: Psikhiatriia: natsionalnoe rukovodstvo. Pod red. Neznanova N.G., Aleksandrovskogo Yu.A. M. 2018.
Psikhiatriia. Natsionalnoe rukovodstvo. Kratkoe izdanie. Pod red. Dmitrievoj T.B., Krasnova V.N., Neznanova N.G., Semke V.Ia., Tiganova A.S. M. 2012.
Metodicheskie rekomendatsii po otsenke vliianiia na biudzhet v ramkakh realizatsii programmy gosudarstvennykh garantii besplatnogo okazaniia grazhdanam meditsinskoi pomoshchi. M.: FGBU «Tsentr ekspertizy i kontrolia kachestva meditsinskoi pomoshchi»; 2016.
Marder S, Davis J, Chounart G. The effects of resperidone on the five dimentions of schizophrenia derived by factor analysis: combined results of the North America Trials. J Clin Psychiatry. 1997;58:12:538-546. https://doi.org/10.4088/jcp.v58n1205
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. https://doi.org/10.1016/S0140-6736(13)60733-3
Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. https://doi.org/10.1016/S0140-6736(19)31135-3
Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014b;171:169-177. https://doi.org/10.1176/appi.ajp.2013.13070985
Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014a;171:160-168. https://doi.org/10.1176/appi.ajp.2013.13070985
Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: Post-hoc analysis of a long-term, double-blind continuation study. Schizophrenia Research. 2015;166:334-338. https://doi.org/10.1016/j.schres.2015.06.008
Harvey PD, Siu C, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo-and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013;23:1373-1382. https://doi.org/10.1016/j.euroneuro.2013.08.003
Mosolov SN. Shkaly psikhometricheskoi otsenki simptomatiki shizofrenii i kontseptsiia pozitivnykh i negativnykh rasstroistv. M.: Novyi tsvet; 2001.
Mosolov SN, Kuzavkova MV, Kalinin VV, Eremin AV, Sulimov GIu. Analiz vliianiia atipichnykh antipsikhotikov na 5-faktornuiu model shizofrenii. Sotsialnaia i klinicheskaia psikhiatriia. 2003;13:3:45-52.
Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004;65:551-556. https://doi.org/10.4088/jcp.v65n0416
Loebel A, Cucchiaro J, Silva R, Mao Y, Xu J, Pikalov A, Marder SR. Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies. European Psychiatry. 2015;30:26-31. https://doi.org/10.1016/j.eurpsy.2014.08.001
Mosolov SN, Maliutin AV, Pikalov AA. Ispolzovanie piatifaktornoi dimensionalnoi shkaly simptomov shizofrenii dlia otsenki terapevticheskogo deistviia lurazidona: obieedinennyi analiz dannykh dvukh kratkosrochnykh randomizirovannykh dvoinykh slepykh platsebo-kontroliruemykh issledovanii na populiatsii patsientov Rossii i Ukrainy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(12):20-28. (In Russ.). https://doi.org/10.17116/jnevro201911912120
Nasrallah HA, Cucchiaro JB, Yongcai M, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectrums. 2015;20:140-147. https://doi.org/10.1016/j.jpsychires.2013.01.020
Mosolov SN, Kapiletti SG, Zhigareva NP, Shafarenko AA, Ryvkin PV, Kostiukova AB, Padkin SE. Dlitelnaia terapiia sertindolom bolnykh shizofreniei s preobladaniem negativnoi simptomatiki. Sovremennaia terapiia psikhicheskikh rasstroistv. 2011;2:17-25.
Instruktsiia po meditsinskomu primeneniiu preparata lurazidon (Latuda). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=602aa9b9-50a7-42fc-adef-4af0fb8b71d9&t=